98%
921
2 minutes
20
Hypercholesterolemia is a recognized comorbidity of Alzheimer's disease (AD), yet its mechanistic connection to AD pathology, particularly its impact on microglial function and amyloid-beta (Aβ) dynamics remains unclear. To investigate this, we utilized the APP (AK) mouse model, which develops robust Aβ pathology, and the APP;LDLR (AL) model, which combines Aβ pathology with LDL receptor deficiency to induce hypercholesterolemia under a Western diet (WD). These models were designed to study the combined effects of genetic predisposition and dietary factors on AD progression. At six months of age, mice were maintained on a control diet or switched to a WD for two months to induce hypercholesterolemia. Our findings demonstrate that hypercholesterolemia suppresses microglial responses to Aβ plaques, evidenced by reduced clustering and activation of microglia around plaques. The combination of WD and LDLR deficiency synergistically diminished the expression of disease-associated microglia markers, resulting in reduced Aβ plaque compactness. Mechanistically, RNA sequencing revealed hypercholesterolemia impaired microglial mitochondrial function, reduced protein synthesis, and heightened neuroinflammation. Lipidomic profiling revealed significant changes in the microglial lipidome, including elevated ceramides, hexosylceramides, and lysophosphatidylcholine, along with reduced N-acylethanolamines, reflecting a pro-inflammatory and metabolically stressed microglial state. Behavioral analyses further revealed that both WD and LDLR deficiency independently and synergistically impaired cognitive performance and increased anxiety-like behaviors in AD mice. Together, this study highlights the role of hypercholesterolemia in exacerbating AD pathology by disrupting microglial function, altering lipid metabolism, and impairing cognitive function, and suggests that pharmacological management of hypercholesterolemia could slow AD progression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.expneurol.2025.115272 | DOI Listing |
Front Genet
August 2025
Federal Medical and Biologicl Agency, Moscow, Russia.
Background: Familial hypercholesterolemia (FH) is a prevalent hereditary disorder, with its monogenic form linked to an elevated risk of early-onset ischemic heart disease. Evaluating the prevalence and penetrance of pathogenic and likely pathogenic variants associated with this disorder would provide valuable information supporting routine FH screening of the general population. Such informed screening would facilitate early identification of at-risk individuals, enabling timely intervention and management.
View Article and Find Full Text PDFAten Primaria
September 2025
Gerencia de Atención Primaria de Gran Canaria, Las Palmas de Gran Canaria, España.
Aim: To describe the percentage of abdominal aortic aneurysm (AAA) cases in the Maspalomas Basic Health Zone among males aged 65 to 75 years who are current or former smokers. Our secondary objectives were to define the distribution of known risk factors for AAA development in our sample and to facilitate early referral to the appropriate vascular surgery service. We also aim to describe the percentage of subaneurysm cases, offering ultrasound follow-up at our center.
View Article and Find Full Text PDFJ Mol Histol
September 2025
Department of Cardiovascular Medicine, Jiangxi Provincial People's Hospital/The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China.
Robinin (RB) is an accepted antioxidant herbal product with known cardio-protective activity. To explore the anti-oxidative potential of RB in treating myocardial ischemia or reperfusion (MI/RI) damage in rats after inducing hypercholesterolemia (HC). HC was induced by administering cholesterol (2%) to rats for eight weeks.
View Article and Find Full Text PDFMed Sci (Paris)
September 2025
Sorbonne Université, Inserm UMRS1269, Nutrition et obésités : approches systémiques, Nutriomics, Paris, France.